Systematic review of outcome measures following chemoradiotherapy for the treatment of anal cancer (CORMAC).
AffiliationDivision of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Vaughan House, Portsmouth Street, Manchester, M13 9GB
MetadataShow full item record
AbstractSix Phase III randomized trials have determined the effectiveness of chemoradiotherapy as primary treatment for anal squamous cell carcinoma (ASCC), but outcomes reported in these trials varied widely, hindering evidence synthesis. To improve reporting in all future trials, we aim to develop a core outcomes set (COS). As the first stage of COS development, we undertook a systematic review to summarize the outcomes reported in studies evaluating chemoradiotherapy for ASCC.
CitationSystematic review of outcome measures following chemoradiotherapy for the treatment of anal cancer (CORMAC). 2018, 20(5): 371-382 Colorectal Dis
- Core outcome research measures in anal cancer (CORMAC): protocol for systematic review, qualitative interviews and Delphi survey to develop a core outcome set in anal cancer.
- Authors: Fish R, Sanders C, Williamson PR, Renehan AG
- Issue date: 2017 Nov 22
- Clinical endpoints in trials of chemoradiation for patients with anal cancer.
- Authors: Glynne-Jones R, Adams R, Lopes A, Meadows H
- Issue date: 2017 Apr
- A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus.
- Authors: Fish R, Sanders C, Adams R, Brewer J, Brookes ST, DeNardo J, Kochhar R, Saunders MP, Sebag-Montefiore D, Williamson PR, Renehan AG
- Issue date: 2018 Dec
- Chemoradiotherapy for anal cancer: are we as good as we think?
- Authors: Martin D, Rödel C, Fokas E
- Issue date: 2019 May
- Review of anal cancer patients at the Ottawa hospital.
- Authors: Abunassar M, Reinders J, Jonker DJ, Asmis T
- Issue date: 2015 May